News PROTHERA BIOLOGICS NEWS April 23, 2020 ProThera Biologics and Takeda Enter Global Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP) June 2019 ProThera Biologics Awarded $2 Million Fast Track NIH GrantCompany is Developing Important Biomarker to Assess Outcomes in Neonates with Sepsis or Necrotizing Enterocolitis (NEC) in Support of its Therapeutic Development Programs June 2017 ProThera Biologics Awarded $1.95-Million NIH GrantCompany and Women & Infants Hospital to Use Funding to Study Treatment for Infant Brain Injury November 2016 ProThera Biologics announces funding from the Rhode Island Commerce Corporation for a collaboration with Rhode Island Hospital to study the association between IAIP levels and disease severity in sepsis patients. September 2016 Slater Reinvests in ProThera Biologics; Commits Additional $250,000to Biomedical Company Developing Novel Anti-Inflammatory Drug January 2016 Providence Journal Profile in Innovation: Capital for Science – Cancer researcher’s path leads to biomedical startup in Providence May 2015 ProThera Biologics Appoints Denice M. Spero, Ph.D. President and Chief Business Officer September 2012 Slater-Backed Biomedical Company Secures $750,000 in Funding, Appoints Slater Venture Partner to Board of Directors June 2010 Slater-Backed Biomedical Company Awarded Nearly $3 Million in Grant Funding, Achieves Additional Progress Toward Commercialization June 2008 Slater Technology Fund Invests in ProThera Biologics. Commits $500,000 to Biomedical Startup Developing Novel Treatments for Sepsis, Cancer and Anthrax Intoxication June 2006 ProThera Biologics Awarded Grants from the National Institutes of Health for Major Unmet Medical Needs. Start-Up Company Received $2.8 Million to Develop Promising Treatments for Sepsis and Anthrax Intoxication
